Sesen Bio, Inc. (SESN)
After hours:
| Previous close | 0.5000 |
| Open | 0.5006 |
| Bid | 0.4934 x 1300 |
| Ask | 0.5150 x 1800 |
| Day's range | 0.4500 - 0.5200 |
| 52-week range | 0.3650 - 6.0400 |
| Volume | |
| Avg. volume | 3,882,214 |
| Market cap | 98.635M |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
CAMBRIDGE, Mass., May 09, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2022. During the quarter, the Company continued to engage with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for Vicineum™ for the treatment
- Business Wire
Sesen Bio Provides Strategic Update
CAMBRIDGE, Mass., May 03, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of the Company, a merger, acquisition or other business combination, a strategic par
- Business Wire
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
CAMBRIDGE, Mass., February 28, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2021. During the fourth quarter, the Company worked with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for the Compan
